G-Quadruplexes, noncanonical nucleic acid structures, act as silencers in the promoter regions of human genes; putative G-quadruplex forming sequences are also present in promoters of other mammals, yeasts, and prokaryotes. Here we show that also the HIV-1 LTR promoter exploits G-quadruplex-mediated transcriptional regulation with striking similarities to eukaryotic promoters and that treatment with a G-quadruplex ligand inhibits HIV-1 infectivity. Computational analysis on 953 HIV-1 strains substantiated a highly conserved G-rich sequence corresponding to Sp1 and NF-κB binding sites. Biophysical/biochemical analysis proved that two mutually exclusive parallel-like intramolecular G-quadruplexes, stabilized by small molecule ligands, primarily fold in this region. Mutations disrupting G-quadruplex formation enhanced HIV promoter activity in cells, whereas treatment with a G-quadruplex ligand impaired promoter activity and displayed antiviral effects. These findings disclose the possibility of inhibiting the HIV-1 LTR promoter by G-quadruplex-interacting small molecules, providing a new pathway to development of anti-HIV-1 drugs with unprecedented mechanism of action.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791109PMC
http://dx.doi.org/10.1021/jm400914rDOI Listing

Publication Analysis

Top Keywords

hiv-1 ltr
8
ltr promoter
8
treatment g-quadruplex
8
g-quadruplex ligand
8
promoter activity
8
promoter
6
hiv-1
5
dynamic g-quadruplex
4
g-quadruplex region
4
region regulates
4

Similar Publications

The HIV integrase inhibitor, dolutegravir (DTG), in the absence of eliciting integrase (int) resistance, has been reported to select mutations in the virus 3'-polypurine tract (3'-PPT) adjacent to the 3'-LTR U3. An analog of DTG, cabotegravir (CAB), has a high genetic barrier to drug resistance and is used in formulations for treatment and long-acting pre-exposure prophylaxis. We examined whether mutations observed for DTG would emerge in vitro with CAB.

View Article and Find Full Text PDF

30 years of HIV therapy: Current and future antiviral drug targets.

Virology

December 2024

Section of Infectious Diseases, Department of Internal Medicine, Yale University, New Haven, CT, 06510, USA. Electronic address:

Significant advances in treatment have turned HIV-1 into a manageable chronic condition. This has been achieved due to highly active antiretroviral therapy (HAART), involving a combination regimen of medications, including drugs that target Reverse Transcriptase, Protease, Integrase, and viral entry, explored in this review. This paper also highlights novel therapies, such as Lenacapavir, and avenues toward functional cure targeting the CCR5 co-receptor, including the Δ32 mutation.

View Article and Find Full Text PDF

Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation.

J Virol

December 2024

Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.

Article Synopsis
  • HIV-1 can integrate into host chromosomes, creating a latent reservoir that makes curing the infection difficult; activating this latency is crucial for eradication.
  • Tannic acid (TA) has been identified as a potential latency-reversing agent, effectively reactivating multiple proviruses and showing synergy with other agents.
  • TA works by degrading a protein called CBX4, which reduces a specific histone modification (H3K27me3) and enhances the transcriptional activity of HIV-1, suggesting a new strategy for targeting HIV-1 latency.
View Article and Find Full Text PDF

Drug abuse continues to pose a significant challenge in HIV control efforts. In our investigation, we discovered that cocaine not only upregulates the expression of the DNA-dependent protein kinase (DNA-PK) but also augments DNA-PK activation by enhancing its phosphorylation at S2056. Moreover, DNA-PK phosphorylation triggers the higher localization of the DNA-PK into the nucleus.

View Article and Find Full Text PDF

The host restriction factor SERINC5 inhibits HIV-1 transcription by negatively regulating NF-κB signaling.

J Biol Chem

December 2024

National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China; Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun, China. Electronic address:

Serine incorporator 5 (SER5) can be incorporated into HIV-1 virions to block viral entry by disrupting the envelope glycoprotein-mediated viral fusion to the plasma membrane. Recent studies suggest that SER5 also inhibits HIV-1 mRNA transcription and the subsequent progeny virion biogenesis. However, the underlying mechanisms through which SER5 antagonizes the viral transcription remain poorly understood.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!